Clinuvel Pharmaceuticals Ltd (AU:CUV) — Market Cap & Net Worth
Market Cap & Net Worth: Clinuvel Pharmaceuticals Ltd (CUV)
Clinuvel Pharmaceuticals Ltd (AU:CUV) has a market capitalization of $326.84 Million (AU$461.92 Million) as of August 4, 2026. Listed on the AU stock exchange, this Australia-based company holds position #14303 globally and #378 in its home market, demonstrating a -8.95% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Clinuvel Pharmaceuticals Ltd's stock price AU$9.16 by its total outstanding shares 50427898 (50.43 Million). See CUV capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
Clinuvel Pharmaceuticals Ltd Market Cap History: 2015 to 2026
Clinuvel Pharmaceuticals Ltd's market capitalization history from 2015 to 2026. Data shows growth from $92.72 Million to $326.84 Million (11.84% CAGR).
Index Memberships
Clinuvel Pharmaceuticals Ltd is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Australia All Ordinaries
AORD
|
$2.04 Trillion | 0.02% | #253 of 495 |
|
S&P/ASX 200
AXJO
|
$1.92 Trillion | 0.02% | #156 of 200 |
|
S&P/ASX 200 Accumulated
AXJOA
|
$1.92 Trillion | 0.02% | #156 of 200 |
|
S&P/ASX 300
AXKO
|
$2.18 Trillion | 0.01% | #237 of 300 |
|
ASX Small Ordinaries
AXSO
|
$291.74 Billion | 0.11% | #145 of 200 |
Weight: Clinuvel Pharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Clinuvel Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Clinuvel Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.68x
Clinuvel Pharmaceuticals Ltd's market cap is 4.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
12.29x
Clinuvel Pharmaceuticals Ltd's market cap is 12.29 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $262.64 Million | $6.82 Million | -$3.12 Million | 38.51x | N/A |
| 2017 | $288.73 Million | $16.77 Million | $7.18 Million | 17.22x | 40.21x |
| 2018 | $638.80 Million | $25.49 Million | $13.22 Million | 25.06x | 48.31x |
| 2019 | $1.01 Billion | $31.05 Million | $18.13 Million | 32.37x | 55.42x |
| 2020 | $789.44 Million | $32.57 Million | $16.65 Million | 24.24x | 47.42x |
| 2021 | $963.05 Million | $47.98 Million | $24.73 Million | 20.07x | 38.95x |
| 2022 | $768.54 Million | $65.72 Million | $20.88 Million | 11.69x | 36.81x |
| 2023 | $569.01 Million | $78.32 Million | $30.60 Million | 7.27x | 18.59x |
| 2024 | $430.31 Million | $88.18 Million | $35.64 Million | 4.88x | 12.08x |
| 2025 | $444.58 Million | $95.02 Million | $36.17 Million | 4.68x | 12.29x |
Competitor Companies of CUV by Market Capitalization
Companies near Clinuvel Pharmaceuticals Ltd in the global market cap rankings as of August 4, 2026.
Key companies related to Clinuvel Pharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
Clinuvel Pharmaceuticals Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Clinuvel Pharmaceuticals Ltd's market cap moved from $92.72 Million to $ 326.84 Million, with a yearly change of 11.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$326.84 Million | -26.48% |
| 2025 | AU$444.58 Million | +3.32% |
| 2024 | AU$430.31 Million | -24.38% |
| 2023 | AU$569.01 Million | -25.96% |
| 2022 | AU$768.54 Million | -20.20% |
| 2021 | AU$963.05 Million | +21.99% |
| 2020 | AU$789.44 Million | -21.45% |
| 2019 | AU$1.01 Billion | +57.33% |
| 2018 | AU$638.80 Million | +121.24% |
| 2017 | AU$288.73 Million | +9.93% |
| 2016 | AU$262.64 Million | +183.26% |
| 2015 | AU$92.72 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Clinuvel Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $326.84 Million USD |
| MoneyControl | $326.84 Million USD |
| MarketWatch | $326.84 Million USD |
| marketcap.company | $326.84 Million USD |
| Reuters | $326.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with e… Read more